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Summary
Introduction: Intraoral mandibular repositioner appliances (IOMRAs) are designed to
enlarge pharyngeal airway space advancing the mandible and increasing genioglossus
tone during sleep. Obstructive sleep apnea syndrome (OSAS) treatment with IOMRAs
is beneficial, but there is a lack of studies in the literature defining the targetee front matter & 2005
med.2005.10.002
ing author. Tel.: +55 11
ess: macmachado@uol.population more inclined to respond to this treatment.
Methods: We contacted by telephone 188 previously treated patients with IOMRA,
detecting 20 not improved patients (Study Group). Twenty improved patients of the
remaining 168 were randomly paired according to gender, age, apnea, and hypopnea
index as Control Group. Both groups answered questionnaires for diagnosis of sleep
disorders, depression, anxiety, and the Epworth sleepiness scale. We did a
descriptive and inferential statistical analysis. The inferential analysis was divided
into two steps: univariate analysis using Fischer exact test and a multiple inferential
analysis using a stepwise regression model.
Results: Although the final model included only insomnia, we concluded that the
presence of gastric, neurological and rheumatic diseases also tended to be
associated with the self-perception of non-improvement. The association between
the accumulation of gastric, neurological, and rheumatic diseases and insomnia and
improvement demonstrated that an increase in one of these diseases correspond to a
two-fold increase in the chance of non-improvement.Elsevier Ltd. All rights reserved.
5571 4493; fax: +55 11 5083 1324.
com.br (M.A.C. Machado).
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Co-morbidities in sleep apnea treated with oral appliance 989Conclusions: Insomnia was the most important factor compromising the success of
OSAS treatment with IOMRAs, and the isolated presence of gastric, neurological and
rheumatic diseases, but especially their combination, reduces the perception rate of
well-succeeded treatment with IOMRAs.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The installation of intraoral devices for the treat-
ment of obstructive sleep apnea syndrome (OSAS)
has become an important therapy, and has the
objective to prevent collapse of the base of the
tongue against the lateral and posterior walls of the
pharynx during sleep, an event increasing the
critical occlusal pressure.1–3 Intraoral devices are
designed to augment pharyngeal airway space
through mandibular protrusion and through an
increase in the vertical dimension of the occlusion
and in genioglossus muscle tonus as a consequence
of the new position of the mandible.1,4–7
A small passive opening of the mandible increases
genioglossus tonus through the activation of re-
ceptors located in the temporomandibular joint,
resulting in a significant increase in the electro-
myographic amplitudes of the genioglossus and
lateral pterygoid muscles during the use of intraoral
mandibular repositioning appliances (IOMRAs).8,9
Mandibular repositioning by means of intraoral
devices for the treatment of OSAS is simple,
reversible, silent, and of low cost. This treatment
modality is currently gaining considerable space in
the scientific scenario; including blood pressure
lowering, although further studies are still neces-
sary to better understand the entire physiopathol-
ogy of OSAS and the action of these intraoral
devices on this condition.10,11,12
Various studies in the literature have demon-
strated the causes of treatment failure of OSAS
with continuous positive airway pressure and
although there are reports citing side effects or
complications with the use of IOMRAs, only few
studies have reported the causes of treatment
failure of OSAS with IOMRAs.13–15
In our clinical practice we noted that some
patients report no clinical improvement except for
the absence of snoring or normalization of the
apnea index upon polysomnography. This observa-
tion motivated the present study in which we
compared the clinical variables of two groups of
patients treated with IOMRAs, one of them report-
ing no satisfactory clinical improvement and the
other reporting that treatment was highly effec-
tive. The main hypothesis of this study was that
OSAS-associated co-morbidities are the cause ofpatient’s report of treatment failure with IOMRAs.
We designed this study to investigate if associated
diseases can reduce the patient feeling of improve-
ment with IOMRAs treatment.Method
Sample
A total of 188 patients of either sex ranging in age
from 25 to 72 years and treated with IOMRAs (Fig.
1). All patient included in this research had two or
more all night polysomnographic study. We in-
cluded sleep related respiratory disorders patients
with polysomnographic diagnostic of mild (5–15
events per hour), moderate (16–30 events per hour)
and severe (more than 30 events per hour) OSAS
and also loud snoring, during the period from 1999
to 2003.
Polysomnography
Standard polysomnographic techniques were em-
ployed and are outlined briefly here. Surface
electroencephalographic electrodes places at C3-
A2 and C4-A1, a submetal electrode, and left and
right electrooculograms were used to stage sleep. A
finger oximeter (Criticare-Systems INC Pulse 504)
recorded oxyhemoglobin saturation (SaO2). A con-
tinuous electrocardiogram recorded heart rate and
rhythm. A digital polygraph (Neurotec model EQSA-
400-1) recorded all physiological data throughout
the night.
Clinical data
In order to detect the presence or absence of
clinical improvement after the end of the protocol,
one of the authors not involved with the treatment
Lucila Bizari Fernandes do Prado (LBFP) contacted
the patients by telephone asking the following
question: ‘‘Did your main complaint improve with
the use of the IOMRA?’’ When the patient had
difficulty understanding the question, the research-
er provided a detailed explanation so that the
patient could completely understand his/her
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188 patients 
Mild-Moderate-Severe OSAS 
1999-2003 
Phone Call Asking: “Did your main 
complaint improve with the use of the 
IOMRA?” 
20 patients 
Felt no clinical improvement 
Besides AHI ≤ 10h 
168 patients 
Felt clinical improvement 
With   AHI ≤10h  
Matching by BMI, Age, 
 AHI pre treatment
20 patients 
Study Group 
   Sleep Questionnaires and interviews 
20 patients 
Control Group 
* 
•  When more than two patients matched in the control group with one in the study group,
    we randomly drew one of them.
Figure 1 Fluxogram.
M.A.C. Machado et al.990health status possibly resulting from OSAS (snoring,
fatigue, and sleepiness, or any other symptom that
made the patient to see a sleep specialist). Twenty
of the 188 patients did not show clinical improve-
ment of the sleep related symptoms that they
arrived with and comprised the Study Group. The
Control Group consisted of 20 patients drawn
among the remaining 168 patients with the same
characteristics as the Study Group, except for the
fact that they had reported clinical improvement
of the sleep related symptoms after treatment.
When more than one patient fulfilled the criteria of
the control group the inclusion were done by
drawing lots.The two groups were matched for gender, age,
body mass index (BMI), and apnea–hypopnea index
(Table 1).
In addition to signing a free informed consent
form, the two groups were submitted at home to
the Johns Hopkins questionnaire for the diagnosis of
sleep disorders, the Beck Inventory for the evalua-
tion of depression, the State-Trait Anxiety Inven-
tory for the evaluation of anxiety, and the Epworth
Sleepiness Scale for the assessment of excessive
daytime sleepiness.16–20 All patients in this study
provided information about their general health
status through the one or more of the following:
(1) chart review, (2) clinical questionnaire attached
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Table 1 Demographic data and apnea–hypopnea index pre- and post treatment showing no differences between
groups.
Study Group (20) Control Group (20) P
Age (yr) 55.277.7 55.677.7 0.91
BMI (kg/m2) 27.373.4 27.473.9 0.93
Gender 4 F and 16M 4 F and 16M —
AHI pre treatment 22.4716.4 18.4711.2 0.30
AHI post treatment 4.673.1 2.872 0.17
Co-morbidities in sleep apnea treated with oral appliance 991to the sleep questionnaire, (3) clinical interview,
and (4) phone interview. We did not have problem
with this research step, because patients that
reported improvement were very determined in
their opinion and those that felt that they did not
improved also stated their opinion vigorously and
took the chance to ask for new treatment options
available. We choose a phone call (made by one
research (LBFP) not involved directly with the
treatment) to ask the patients if they felt improve-
ment with IOMRAs treatment because we think this
procedure allows more freedom to the patient to
give his/her sincere opinion far from his/her health
care professional.
Insomnia was diagnosed if the patients reported
that they have problem of initiating or maintaining
sleep for at least 5 days per week and for more than
6 months. We grouped in the category Gastric
Disease those patients with heart burning, endo-
scopic diagnosis of hiatus hernia, gastritis, esopha-
gitis, and other gastric related complaints; in the
category Rheumatic Disease patients with osteoar-
thritis, and all sort of degenerative aging-related
joint disease affecting mainly the knees, lumbar
column and hip joint; in the category Neurological
Disease patients with headache, migraine, vertigo
complaints, history of seizure or epilepsy (we did
not have patients with degenerative disease,
stroke, cerebelar ataxia or any other severe
neurological condition); in the category Psychiatric
Disease patients in treatment for or with recent
history of depression, anxiety, panic disorder or
other psychiatric condition.
Variables like BMI, race, educational level,
rotation shift, smoking, drinking, caffeine inges-
tion, medications, sedatives, insufficient sleep
among others were obtained mostly throughout
our sleep and clinical questionnaire, but also by
chart review or personal interview as mentioned
above. We did not use the phone interview to
collect those data, because it would take too much
time and also could ensue misinformation.
To be included in the study all patients should
attend two essential conditions: (1) to have a
clinical and laboratorial polysomnographic diagno-sis of mild (5–15 events per hour), moderate (16–30
events per hour) or severe (more than 30 events per
hour) OSAS or of increased upper airway resistance
syndrome according to the criteria of the American
Academy of Sleep Medicine.21; and (2) to have a
follow up polysomnography at the end of IOMRAs’
titration showing less than 10 events per hour. The
main complaints of these patients were snoring
which disturbed the partner, fatigue, and excessive
daytime sleepiness.
The IOMRAs were fabricated with two dental plates
consisting of self-polymerizing acrylic resin, one for
the upper arch and one for the lower arch with
complete coverage of the occlusal sides of the teeth.
A stainless-steel device containing a thread that
permits millimeter adjustments connected the two
plates in such a way that when activating the thread
of the metallic device the lower plate was moved
forward, promoting mandibular advancement.Intervention
The patients were submitted to a clinical follow-up
protocol, which consisted of a weekly visit for 4
months after installation of the intraoral device. On
each visit, the patient was asked about his/her
clinical condition (snoring, sleepiness and fatigue)
and about problems with the use of the device. The
IOMRA was then adjusted to promote mandibular
advancement, which was on average 0.5mm per
week until the most comfortable mandible protru-
sive position for each patient. Satisfactory ad-
vancement of the mandible was achieved in all
patients at the end of 4 months, and the adjust-
ment procedure was discontinued when the patient
reported the disappearance of snoring and clinical
improvement in sleepiness and fatigue. When some
symptoms persisted, the disappearance of snoring
was considered to be an indicator of the efficacy of
mandibular advancement with the IOMRA and
adjustment was discontinued. After this adjust-
ment period, the patients were referred to the
medical teams for clinical and laboratorial poly-
somnographic reassessment. Control laboratorial
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place during the exam.Table 2 Univariate inferential analysis of the
association between diseases and improvement.
Variable P
Insomnia 0.022
Gastric diseases 0.058
Neurologic diseases 0.127
Rheumatologic diseases 0.168Statistical analysis
Statistical analysis was divided into two parts:
descriptive and inferential analysis. Descriptive
analysis permitted the determination of relevant
interacting factors (combination of two variables).
Inferential analysis was divided into two steps:
first, univariate analysis was performed to deter-
mine the association between each variable and
improvement using the w2 or Fisher exact test to
identify which variables showed the strongest
association with improvement upon this type of
analysis.22 Next, multiple inferential analysis was
performed as follows: an intermediate model was
constructed using a stepwise logistic regression
model, with an entry probability of 0.15 and an exit
probability of 0.25.23
Possible interactions suggested by the descrip-
tive analysis, which showed an association with the
variables of the intermediate model were then
investigated. The variables considered to enter the
final model were: BMI, race, educational level,
rotation shift, working at night, smoking, drinking,
caffeine ingestion, snacks at night, diseases, use of
medications, sedatives, insufficient sleep, insom-
nia, restless leg syndrome, and periodic limb
movements in sleep (PLMS).
Possible interactions effects were investigated
observing the relationship between lack of im-
provement and each independent variable at
different levels of other independent variables.
We seek for changes in the odds ratio that we
considered important when comparing the levels at
the second independent variable but without any
fixed rule due to the fact that we concern other
aspect: clinical relevance of the two independent
variables. Doing these we tried to exclude spurious
associations, always taking in account that the
sample size may not be sufficient to show relevant
interactions. The combinations of variables con-
sidered to be relevant upon descriptive analysis
were BMI and drinking, BMI and insomnia, drinking
and gastric disease, drinking and insomnia, heart
and rheumatologic disease, gastric disease and
insufficient sleep, neurological and psychiatric
disease, neurological disease and insufficient sleep,
insufficient sleep and insomnia, and psychiatric
disease and use of medications.
Since insomnia was the only variable remaining in
the intermediate model (P ¼ 0:022), no interacting
factors were investigated and therefore the final
model contained only the variable insomnia.Univariate analysis revealed a strong association
between the lack of improvement and the following
variables: drinking (P ¼ 0:159), caffeine ingestion
(P ¼ 0:206), gastric disease (P ¼ 0:058), rheumato-
logic disease (P ¼ 0:168), neurological disease
(P ¼ 0:127), and insomnia (P ¼ 0:022). The variable
PLMS was discarded because it was only present in
three individuals. Since one possible hypothesis for
unsuccessful treatment is the general health
status, improvement-related accumulation of the
following main diseases obtained by univariate
analysis was also investigated: gastric, rheumato-
logic and neurological diseases, and insomnia. The
association between improvement and the accu-
mulation of diseases was determined using a simple
logistic regression model. Accumulation of diseases
was defined as a disease index and was calculated
by the following formula: disease index ¼ gastric
disease+neurological disease+rheumatologic disea-
se+insomnia, where the presence or absence of
each disease was scored as 1 or 0, respectively. The
disease index construction was based on our
intuition that some of the diseases studied have
accumulative contribution to the lack of improve-
ment, i.e., a person with just one of the diseases
would have a better improvement when comparing
with a person with two or more of the established
diseases. The diseases were chosen using the
univariate analysis and selecting the diseases with
P-values lower than 0.20 when studying the
relationship between these variables and the lack
of improvement: gastric disease (P ¼ 0:058), rheu-
matologic disease (P ¼ 0:168), neurological disease
(0.127) and insomnia (P ¼ 0:022).Results
Demographic data were not different between
control and study groups substantiating our match-
ing procedure (Table 1).
Insomnia was associated with the lack of clinical
improvement when using an IOMRA (Po0:02;
Table 2), with the expected chance of improvement
being five times higher for subjects without
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Table 3 Logistic regression model using the disease index.
Variable Coefficient Standard error P Chance ratio 95% confidence interval
Lower limit Upper limit
Disease index 0.761 0.324 0.019 2.141 1.135 4.038
Table 4 Distribution of improvement according
to disease index.
Disease index Improvement Total
Yes No
0 7 (78%) 2 (22%) 9 (100%)
1 6 (60%) 4 (40%) 10 (100%)
2 5 (46%) 6 (55%) 11 (100%)
3 2 (33%) 4 (67%) 6 (100%)
4 0 (0%) 4 (100%) 4 (100%)
Total 20 (50%) 20 (50%) 40 (100%)
Co-morbidities in sleep apnea treated with oral appliance 993insomnia compared to those with insomnia.
Although the final model included only insomnia,
univariate inferential analysis showed that the
presence of gastric, neurological and rheumatic
diseases also tended to be associated with the lack
of improvement (Table 2).
Analysis of the association between the accumu-
lation of gastric, neurological and rheumatic dis-
eases and insomnia (disease index; Table 3) and
improvement demonstrated that an increase in one
of these diseases corresponded to a two-fold
increase in the chance of non-improvement, i.e.,
the higher the disease index, the higher the
proportion of patients who did not show improve-
ment (P ¼ 0:02) (Table 4 and Fig. 2).0%
10%
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80%
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Figure 2 Improvement versus disease index.Discussion
To our knowledge, this is the first study trying to
determine the causes of failure report of IOMRA
treatment in well-indicated cases of OSAS. Treat-
ment of OSAS with intraoral devices has been a
matter of intensive discussion in the literature over
the last two decades, with most studies trying to
prove the efficacy of IOMRAs in the treatment of
mild and moderate OSAS.1,4,9,11,13
The present study demonstrated that both the
sleep specialist and the dental surgeon should go
beyond the well-established routine considerations
of each specialty and perform a more complete
assessment of the patient. The professional should
survey the clinical history for systemic involve-
ment, mainly gastric, neurological and rheumatic
disorders and the presence of insomnia, which may
compromise the self-perception of the effect of
treatment with IOMRAs. In the present study, global
clinical assessment of the patients permitted the
identification of other factors that had a strong
influence on the clinical evolution of patients
treated with IOMRAs, and we should take care
special attention for the diagnosis of insomnia that
is highly prevalent in apnea patients.24
Care of patients with sleep disorders requires a
wider knowledge of these disorders on the part of
the dental surgeon and successful treatment does
not only depend on a good domination of themanufacturing techniques and adjustment of the
intraoral devices. In addition to providing basic
behavioral guidance to his/her patient, the dentist
should also be able to recognize situations in which
follow-up by a general or specialized clinician is
necessary.
Awareness of the patient regarding his/her
parallel health problems and how they may inter-
fere with the treatment of OSAS with IOMRAs is
fundamental to guarantee success and to prevent
frustration for both the dental surgeon and the
patient. We have already presented data showing
that about 80% of the patients improve upon
treatment with an IOMRA,25 and this study allow
us to suspect that patients who do not improve
probably present co-morbidities associated with
the sleep related respiratory condition, as shown in
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have poor perception of their disease state, and
some symptoms not related to OSAS can be far
more important to them; if the sleep specialist are
not aware, both patient and health professional
end frustrated, and the patient lose the opportu-
nity of seeing other health professional that would
be necessary to manage his/her problem.
We also noticed in our study that the accumula-
tion of diseases (insomnia, gastric, rheumatologi-
cal, and neurological—Fig. 2) drastically reduces
the chances of improvement of the OSAS patients.
Although the relationship between the disease
index and lack of improvement found seems to be
clinically relevant, the reader should always take in
account that this strategy analysis could be
dangerous for those who assume these findings
without regarding the limitations of the sample size
and without regarding the fact that the construc-
tion of the index was based in our intuition and in
the P-values encountered in univariate analysis.
The major limitation of the present study was the
small number of patients in each group, a fact that
might have underestimated the effects of certain
co-morbidities, in addition to reducing the possible
number of variables entering the multivariate
logistic regression model. We therefore suggest
further studies including a larger number of
patients to better define the role of co-morbidities
in the perception of improvement, as well as to
establish treatment-associated strategies.Conclusions
The present study demonstrated that (1) insomnia is
probably the factor that most compromises the
perception of self-improvement after OSAS treat-
ment with IOMRAs; (2) the isolated presence of
gastric, neurological and rheumatic diseases, but
especially their combination, reduces the percep-
tion rate of improvement after treatment with
IOMRAs; (3) the health care professional involved
in the treatment of OSAS should be trained to
provide a more complete assessment of the patient,
irrespective of his specialty, and, finally, (4) patients
selected for treatment with IOMRAs should be
informed that their perception of improvement does
not only depend on the use of an IOMRA but also on
the attention given to their global health status.References
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